These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 28416745)
1. Stable H3 peptide was delivered by gold nanorods to inhibit LSD1 activation and induce human mesenchymal stem cells differentiation. Meng X; Li J; Zheng M; Zuo L; Sun C; Zhu Y; Fang L; Liu L; Zhou X Oncotarget; 2017 Apr; 8(14):23110-23119. PubMed ID: 28416745 [TBL] [Abstract][Full Text] [Related]
2. Gold nanorod delivery of LSD1 siRNA induces human mesenchymal stem cell differentiation. Zhao X; Huang Q; Jin Y Mater Sci Eng C Mater Biol Appl; 2015 Sep; 54():142-9. PubMed ID: 26046277 [TBL] [Abstract][Full Text] [Related]
3. Histone H3 peptide based LSD1-selective inhibitors. Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526 [TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures. Ota Y; Kakizawa T; Itoh Y; Suzuki T Molecules; 2018 May; 23(5):. PubMed ID: 29734782 [TBL] [Abstract][Full Text] [Related]
5. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors. Kakizawa T; Ota Y; Itoh Y; Suzuki T Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865 [TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. Culhane JC; Wang D; Yen PM; Cole PA J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560 [TBL] [Abstract][Full Text] [Related]
7. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1. Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409 [TBL] [Abstract][Full Text] [Related]
10. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505 [TBL] [Abstract][Full Text] [Related]
12. The epigenetic promotion of osteogenic differentiation of human adipose-derived stem cells by the genetic and chemical blockade of histone demethylase LSD1. Ge W; Liu Y; Chen T; Zhang X; Lv L; Jin C; Jiang Y; Shi L; Zhou Y Biomaterials; 2014 Jul; 35(23):6015-25. PubMed ID: 24794925 [TBL] [Abstract][Full Text] [Related]
13. An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors. Zheng YC; Chang J; Zhang T; Suo FZ; Chen XB; Liu Y; Zhao B; Yu B; Liu HM Curr Med Chem; 2017; 24(23):2496-2504. PubMed ID: 28486922 [TBL] [Abstract][Full Text] [Related]
15. Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2). Mino K; Nishimura S; Ninomiya S; Tujii H; Matsumori Y; Tsuchida M; Hosoi M; Koseki K; Wada S; Hasegawa M; Sasaki R; Murakami-Yamaguchi Y; Narita H; Suzuki T; Miyata N; Mizukami T Biosci Biotechnol Biochem; 2014; 78(6):1010-7. PubMed ID: 25036127 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia. Przespolewski A; Wang ES Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors. Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360 [TBL] [Abstract][Full Text] [Related]
18. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation. Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721 [TBL] [Abstract][Full Text] [Related]
19. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation. Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950 [TBL] [Abstract][Full Text] [Related]